501008-41-9 Usage
Uses
Used in Pharmaceutical Industry:
2-Methoxy-5-fluorobenzyl cyanide is utilized as a key intermediate for the synthesis of active pharmaceutical ingredients. Its unique chemical structure allows it to participate in diverse synthetic pathways, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Methoxy-5-fluorobenzyl cyanide is employed in the production of pesticides. Its reactivity and chemical properties make it a valuable component in the creation of effective pest control agents.
Used in Drug Development:
2-Methoxy-5-fluorobenzyl cyanide is used as a precursor in the development of new drugs and biologically active compounds. Its pharmacological and physiological properties offer opportunities for the discovery of innovative therapeutic agents with improved efficacy and selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 501008-41-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,1,0,0 and 8 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 501008-41:
(8*5)+(7*0)+(6*1)+(5*0)+(4*0)+(3*8)+(2*4)+(1*1)=79
79 % 10 = 9
So 501008-41-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H8FNO/c1-12-9-3-2-8(10)6-7(9)4-5-11/h2-3,6H,4H2,1H3
501008-41-9Relevant academic research and scientific papers
SMALL MOLECULE CORRECTORS OF MAMMALIAN SLC6A8 FUNCTION
-
Page/Page column 61; 113, (2022/02/05)
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with mutation in a protein.
MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS
-
Paragraph 145; 227; 228, (2019/10/19)
Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES
-
Page/Page column 40, (2008/06/13)
The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.
